cd80/cd86

Posted by Catalina Garcia on April 4th, 2024

The cluster of differentiation 80, also named CD80 and B7-1, is the type I membrane protein in the immunoglobulin superfamily. It is composed of an extracellular immunoglobulin constant-like domain and a variable-like domain for receptor binding. It is closely related to CD86 and often acts synergistically. The genes are located in the 3q13.3~q21 and 3q21 regions of human chromosomes, respectively. They have 25% amino acid homology, and the extracellular domains are both IgV+IgC.

Studies have shown that a variety of hematological malignancies have low or no expression of CD80 molecules. The transfer of CD80 molecules into tumor cells enhances their immunogenicity and promotes the activation of anti-tumor T cells. Clinical trials have shown that blocking CD28-CD80/CD86 signaling can sensitize chemotherapy drugs and significantly reduce tumor burden. In this case, CD80 has been served as a potential target for drug discovery against various tumors. Now, several CD80-targeting therapeutics have been discovered for tumor treatment.